3-(2',4'-dichlorobiphenyl-3-yl)-5,6-dihydro-2'H,8H-spiro[imidazo[1,2-a]pyridine-7,3'-piperidin]-2'-one | 1610942-96-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 3-(2',4'-dichlorobiphenyl-3-yl)-5,6-dihydro-2'H,8H-spiro[imidazo[1,2-a]pyridine-7,3'-piperidin]-2'-one
• CAS: 1610942-96-5
• 化学式: C₂₃H₂₁Cl₂N₃O
• 分子量: 426.345
• InChiKey: WTYYZOAVASSJDD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.37
• 重原子数：
  29.0
• 可旋转键数：
  2.0
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  46.92
• 氢给体数：
  1.0
• 氢受体数：
  3.0

反应信息

• 作为反应物：
  描述：

  3-(2',4'-dichlorobiphenyl-3-yl)-5,6-dihydro-2'H,8H-spiro[imidazo[1,2-a]pyridine-7,3'-piperidin]-2'-one 在 Column Chiralpak AS 作用下， 以 甲醇 、 三乙胺 为溶剂， 以39%的产率得到(7R)-3-(2',4'-dichlorobiphenyl-3-yl)-5,6-dihydro-2'H,8H-spiro[imidazo[1,2-a]pyridine-7,3'-piperidin]-2'-one
  参考文献：
  名称：

  Design and synthesis of conformationally restricted inhibitors of active thrombin activatable fibrinolysis inhibitor (TAFIa)

  摘要：

  A series of 4,5,6,7-tetrahydro-1H-benzimidazole-5-carboxylic acid and 5,6,7,8-tetrahydroimidazo [1,2-a] pyridine-7-carboxylic acid derivatives designed as inhibitors of TAFIa has been prepared via a common hydrogenation-alkylation sequence starting from the appropriate benzimidazole and imidazopyridine system. We present a successful design strategy using a conformational restriction approach resulting in potent and selective inhibitors of TAFIa. The X-ray structure of compound 5 in complex with a H333Y/H335Q double mutant TAFI indicate that the conformational restriction is responsible for the observed potency increase. (c) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2014.02.010
• 作为产物：
  描述：

  2,4-dichlorophenylboronic acid 、 3-(3-bromophenyl)-5,6-dihydro-2′H,8H-spiro[imidazo[1,2-a]pyridine-7,3′-piperidin]-2′-one 在 四(三苯基膦)钯 、 sodium carbonate 作用下， 以 乙二醇二甲醚 、 水 为溶剂， 反应 2.08h， 以60%的产率得到3-(2',4'-dichlorobiphenyl-3-yl)-5,6-dihydro-2'H,8H-spiro[imidazo[1,2-a]pyridine-7,3'-piperidin]-2'-one
  参考文献：
  名称：

  Design and synthesis of conformationally restricted inhibitors of active thrombin activatable fibrinolysis inhibitor (TAFIa)

  摘要：

  A series of 4,5,6,7-tetrahydro-1H-benzimidazole-5-carboxylic acid and 5,6,7,8-tetrahydroimidazo [1,2-a] pyridine-7-carboxylic acid derivatives designed as inhibitors of TAFIa has been prepared via a common hydrogenation-alkylation sequence starting from the appropriate benzimidazole and imidazopyridine system. We present a successful design strategy using a conformational restriction approach resulting in potent and selective inhibitors of TAFIa. The X-ray structure of compound 5 in complex with a H333Y/H335Q double mutant TAFI indicate that the conformational restriction is responsible for the observed potency increase. (c) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2014.02.010